ABTS vs OXBR
Valuation
Profitability
Growth
Financial Health
Dividends
AI Verdict
ABTS exhibits weak financial health with a Piotroski F-Score of 3/9, indicating significant operational and financial distress. The company reports negative profitability metrics, including a -11.86% profit margin and -8.71% ROE, despite a positive gross margin of 52.33%. Its extremely low current and quick ratios (0.18) signal severe liquidity risk, and the lack of an Altman Z-Score raises red flags for potential bankruptcy. Although revenue grew 6% YoY, the absence of earnings data and negative cash flow metrics undermine growth credibility. The stock trades at a discount to book value (P/B: 0.67), but this is not a value signal given the underlying deterioration in fundamentals.
OXBR exhibits severe financial distress, highlighted by a critical Piotroski F-Score of 1/9, indicating fundamental weakness across almost all health metrics. While the company shows strong top-line revenue growth of 36.5%, this is completely offset by catastrophic profitability, with a profit margin of -80.68% and an ROE of -41.19%. The stock is in a clear technical downtrend, losing over 51% of its value in the last year, and consistently misses earnings estimates by wide margins. Trading at a P/B of 0.95 suggests the market is pricing in the ongoing erosion of the company's book value.
Compare Another Pair
Related Comparisons
ABTS vs OXBR: Head-to-Head Comparison
This page compares Abits Group Inc. (ABTS) and Oxbridge Re Holdings Limited (OXBR) across key fundamental metrics including valuation ratios, profitability margins, growth rates, financial health indicators, and dividend metrics. Each metric highlights the better-performing stock so you can quickly identify relative strengths and weaknesses.
Our AI engine independently analyzes each company's financials, competitive position, and market conditions to produce a verdict (Bullish, Neutral, or Bearish) along with key strengths and risks. Use this comparison alongside your own research to make informed investment decisions.